Aarti Pharmalabs Ltd (AARTIPHARM) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a mixed performance in Q2 FY26, with standalone revenue growing 11% YoY, while consolidated revenue declined.
- Profitability was under pressure, primarily due to margin compression in the API & Intermediates segment and a significant forex loss of INR 7.4 crores on the standalone PAT.
- The CDMO-CMO segment demonstrated strong momentum, with management upgrading its full-year growth guidance to exceed the previously stated 30-40% YoY growth, supported by a robust order book.
- The API & Intermediates business faced challenges from increased competition and inventory correction by customers for products launched last year, leading to a sales mix skewed towards lower-margin APIs.
- Strategic projects are progressing as planned, with the new Atali plant inaugurated in September and the Xanthine capacity expansion on track to reach 9,000 metric tons per annum by the end of FY26.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.